In light of the role of hyperinsulinemia in breast cancer growth and migration [55], the robust insulin-sensitizing anti-diabetic activity of MEDICA [17, 18, 20, 21] may translate to improved treatment of ErbB2 breast cancer in both diabetic and non-diabetic patients. Here, ERBB2 is linked to breast carcinoma.